Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.

Ho PM, Peterson ED, Wang L, Magid DJ, Fihn SD, Larsen GC, Jesse RA, Rumsfeld JS.

JAMA. 2008 Feb 6;299(5):532-9. doi: 10.1001/jama.299.5.532. Erratum in: JAMA. 2008 May 28;299(20):2390.

PMID:
18252883
2.

The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.

Rogowski W, Burch J, Palmer S, Craigs C, Golder S, Woolacott N.

Health Technol Assess. 2009 Jun;13(31):iii-iv, ix-xi, 1-77. doi: 10.3310/hta13310. Review.

3.

Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Aradi D, Komócsi A, Vorobcsuk A, Serebruany VL.

Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29. Review.

PMID:
23197191
4.

Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.

Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Fleeman N, McEntee J, Dundar Y, Richardson M, Fisher M.

Health Technol Assess. 2015 Apr;19(29):1-130. doi: 10.3310/hta19290. Review.

5.

Review of prasugrel for the secondary prevention of atherothrombosis.

Spinler SA, Rees C.

J Manag Care Pharm. 2009 Jun;15(5):383-95. Review.

6.

Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.

Bosch X, Marrugat J, Sanchis J.

Cochrane Database Syst Rev. 2013 Oct 18;(10):CD002130. doi: 10.1002/14651858.CD002130.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;(11):CD002130.

PMID:
24136036
7.

Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Motovska Z, Kala P.

Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Review.

PMID:
19281914
8.

Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.

Gan XD, Wei BZ, Fang D, Fang Q, Li KY, Ding SL, Peng S, Wan J.

Curr Med Res Opin. 2015 Dec;31(12):2313-23. doi: 10.1185/03007995.2015.1098600. Epub 2015 Nov 4. Review.

PMID:
26402735
9.

Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy.

Nairooz R, Valgimigli M, Rochlani Y, Pothineni NV, Raina S, Sardar P, Mukherjee D, Naidu SS, Shavelle DM.

Int J Cardiol. 2017 Feb 15;229:82-89. doi: 10.1016/j.ijcard.2016.11.226. Epub 2016 Nov 12. Review.

PMID:
27887802
10.

Contemporary issues on clopidogrel therapy.

Patti G, Di Sciascio G.

Intern Emerg Med. 2009 Jun;4(3):201-11. doi: 10.1007/s11739-008-0220-5. Epub 2009 Jan 8. Review.

PMID:
19130176
11.

Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials.

Sethi SS, Akl EG, Farkouh ME.

Curr Diab Rep. 2012 Jun;12(3):294-304. doi: 10.1007/s11892-012-0272-9. Review.

PMID:
22528594

Supplemental Content

Support Center